ReviewThe American journal of pathology2023
The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases.
Review in The American journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Beneficial effects of Chlorella species supplementation in the general population: a GRADE-assessed systematic review and dose-response meta-analysis.Nutrition & diabetes · 2026Pooled it
- Efficacy ofNutrients · 2024Trial
- Gut microbiome dysbiosis, short-chain fatty acid depletion and implications for neuroinflammation in atypical parkinsonian syndromes - a systematic review of patient cohorts.Journal of Parkinson's disease · 2026Review
- Review
- Gut-Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3/c-Myc Signaling Axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- From Mechanisms to Practice: Gut Microbiome-Based Strategies for Supporting Recovery in Elite Athletes.Nutrients · 2026Review
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH.International journal of molecular sciences · 2026Review
- Untargeted LC-MS Plasma Metabolomics Reveals Altered Amino Acid and Carbohydrate Metabolism in Dairy Calves Supplemented with Direct-Fed Microbials.Metabolites · 2026Article
- NovelGut · 2026Article
- Short-, medium-, versus long-chain fatty acids: mechanisms of immunomodulation and disease pathogenesis.Cellular & molecular immunology · 2026Review
- Comparative Analysis of Gut Microbiota Patterns in Irritable Bowel Syndrome, Anxiety, and Autoimmune Disorders.Biomedicines · 2026Article
- Therapeutic strategies for hypertension: exploring the role of microbiota-derived short-chain fatty acids in kidney physiology and development.Pediatric nephrology (Berlin, Germany) · 2026Review
- Two Sides of a Coin: Molecular, metabolic, and Phenotypic Convergence in Pediatric Undernutrition and Obesity.Current obesity reports · 2026Review
- Conformable Device for Independent Measurements of Mucosal and Vascular Barriers in a Complex In Vitro Intestinal Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026Review
- Targeting gut-liver-kidney axis: microbiota-derived metabolites and therapeutic implications.Cell communication and signaling : CCS · 2026Review
- Effects of Mixed Fruits and Berries on Ameliorating Gut Microbiota and Hepatic Alterations Induced by Cafeteria Diet.Nutrients · 2026Article
- Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism.Frontiers in immunology · 2026Review
- Multi-omics reveals the associations between cecal candidate bacteria and muscle fatty acid composition variations in Daheng and Luning chickens.Frontiers in microbiology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.